Literature DB >> 2933951

Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonists.

W Kiowski, F R Bühler, M O Fadayomi, P Erne, F B Müller, U L Hulthén, P Bolli.   

Abstract

Age, race, pretreatment blood pressure and plasma renin activity have been related to the antihypertensive response to calcium antagonists in studies that included 215 patients with mild to moderate essential hypertension. Adverse effects necessitated withdrawal from therapy in about 10% of the patients. All calcium antagonists lowered blood pressure significantly and comparably without weight gain or reflex tachycardia. In a multiple linear regression analysis of 138 white patients, age, pretreatment blood pressure and renin activity were of independent and significant predictive value for the antihypertensive response. Stratification of patients into 3 age groups disclosed a greater effect in patients older than 60 years compared with those between 40 and 60 years and those below 40 years, respectively (p less than 0.01). In 16 middle-aged black patients, antihypertensive therapy with a calcium antagonist proved highly efficacious. Monotherapy with a calcium antagonist may become a first-line treatment for essential hypertension, particularly in older patients who have low renin activity and possibly in black patients as well.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933951     DOI: 10.1016/0002-9149(85)90549-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects.

Authors:  J H Ahmed; H L Elliott; P A Meredith; J L Reid
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

Review 2.  Psychopharmacological properties of calcium channel inhibitors.

Authors:  O Pucilowski
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

4.  A comparison of diltiazem and metoprolol in hypertension. Swedish Diltiazem-Metoprolol Multicentre Study Group.

Authors:  T Hedner; T Thulin; S Gustafsson; S O Olsson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

6.  Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.

Authors:  D R Robertson; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

7.  Acute and long-term hemodynamic effects of tiapamil at rest and during exercise in essential hypertension.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 8.  Antihypertensive treatment according to age, plasma renin and race.

Authors:  F R Bühler
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

9.  Diuretic use in black patients with uncontrolled hypertension.

Authors:  Linda M Gerber; Samuel J Mann; Margaret V McDonald; Ya-Lin Chiu; Sridevi Sridharan; Penny H Feldman
Journal:  Am J Hypertens       Date:  2012-12-28       Impact factor: 2.689

Review 10.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.